Major Adverse Dystrophinopathy Event Score as Marker of Cumulative Morbidity and Risk for Mortality in Boys with Duchenne Muscular Dystrophy
暂无分享,去创建一个
C. Almond | D. Rosenthal | B. Kaufman | H. Gordish-Dressman | Zihuai He | T. Duong | Ariadna García | M. Buu | C. Tesi‐Rocha
[1] E. Pegoraro,et al. Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges. , 2022, The Lancet. Respiratory medicine.
[2] M. Link,et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Journal of the American College of Cardiology.
[3] K. Kinnett,et al. Current Practices in Treating Cardiomyopathy and Heart Failure in Duchenne Muscular Dystrophy (DMD): Understanding Care Practices in Order to Optimize DMD Heart Failure Through ACTION , 2022, Pediatric Cardiology.
[4] A. Fernandez-Fernandez,et al. The Minimal Clinical Important Difference (MCID) in Annual Rate of Change of Timed Function Tests in Boys with DMD , 2021, Journal of neuromuscular diseases.
[5] J. Teuteberg,et al. The Stanford acute heart failure symptom score for patients hospitalized with heart failure. , 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[6] C. Almond,et al. The Creation of a Pediatric Health Care Learning Network: The ACTION Quality Improvement Collaborative , 2020, ASAIO journal.
[7] N. Jahan,et al. Major Adverse Cardiovascular Events: An Inevitable Outcome of ST-elevation myocardial infarction? A Literature Review , 2019, Cureus.
[8] S. Nelson,et al. Cardiac MRI biomarkers for Duchenne muscular dystrophy , 2018, Biomarkers in medicine.
[9] A. Pestronk,et al. Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids , 2017, Neuromuscular Disorders.
[10] Carla M Bann,et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management , 2018, The Lancet Neurology.
[11] E. Hoffman,et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study , 2017, The Lancet.
[12] M. Desai,et al. Development and validation of a major adverse transplant event (MATE) score to predict late graft loss in pediatric heart transplantation. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[13] G. Kolovou,et al. Cardiac Involvement in Duchenne Muscular Dystrophy and Related Dystrophinopathies. , 2018, Methods in molecular biology.
[14] M. Drazner,et al. Predictors of Death in Adults With Duchenne Muscular Dystrophy–Associated Cardiomyopathy , 2017, Journal of the American Heart Association.
[15] Paul J. Wang,et al. Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. , 2017, Circulation.
[16] R. Finkel,et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.
[17] W. Hung,et al. The burden of major adverse cardiac events in patients with coronary artery disease , 2017, BMC Cardiovascular Disorders.
[18] K. Bushby,et al. Why are some patients with Duchenne muscular dystrophy dying young: An analysis of causes of death in North East England. , 2016, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[19] B. Byrne,et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy , 2015, Annals of neurology.
[20] P. Gilbert,et al. Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice Definition , 2015, Journal of causal inference.
[21] C. Angelini. Prevention of cardiomyopathy in Duchenne muscular dystrophy , 2015, The Lancet Neurology.
[22] Carmen Cadarso-Suárez,et al. OptimalCutpoints: An R Package for Selecting Optimal Cutpoints in Diagnostic Tests , 2014 .
[23] J. Waltenberger,et al. Left ventricular systolic function and the pattern of late-gadolinium-enhancement independently and additively predict adverse cardiac events in muscular dystrophy patients , 2014, Journal of Cardiovascular Magnetic Resonance.
[24] C. Spurney,et al. Cooperative international neuromuscular research group duchenne natural history study demonstrates insufficient diagnosis and treatment of cardiomyopathy in duchenne muscular dystrophy , 2014, Muscle & nerve.
[25] Jay J. Han,et al. The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measur , 2013, Muscle & nerve.
[26] Jay J. Han,et al. The cooperative international neuromuscular research group duchenne natural history study—a longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used , 2013, Muscle & nerve.
[27] D. Bernstein,et al. Abdominal complaints as a common first presentation of heart failure in adolescents with dilated cardiomyopathy. , 2013, The American journal of emergency medicine.
[28] C. Spurney. Cardiomyopathy of duchenne muscular dystrophy: Current understanding and future directions , 2011, Muscle & nerve.
[29] Peter C. Austin,et al. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research , 2009, Commun. Stat. Simul. Comput..
[30] M. Gonen,et al. Concordance probability and discriminatory power in proportional hazards regression , 2005 .
[31] G. Corrado,et al. Prognostic value of electrocardiograms, ventricular late potentials, ventricular arrhythmias, and left ventricular systolic dysfunction in patients with Duchenne muscular dystrophy. , 2002, The American journal of cardiology.
[32] E. Mattsson,et al. Validity of the EK scale: a functional assessment of non-ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy. , 2001, Physiotherapy research international : the journal for researchers and clinicians in physical therapy.
[34] J. Miller,et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. , 1989, The New England journal of medicine.